ICICI Securities sees 28% UPSIDE in Karur Vysya Bank- Yet another strong quarter with multi-year high RoA of 1.76% and stable asset quality ICICI Securities sees 28% UPSIDE in Karur Vysya Bank- Yet another strong quarter with multi-year high RoA of 1.76% and stable asset quality
Related Posts
#FIIs net sell ₹5,729.60 crore while #DIIs net buy ₹7,000.68 crore in equities today (provisional) MarketTrends https://earnfree.in/latest #COMMODITY #FIIs net sell ₹5,729.60 crore while #DIIs net buy ₹7,000.68 crore in equities today (provisional) MarketTrends https://ift.tt/OMXfhWY #COMMODITY
- Raj Gaurav Rai
- October 8, 2024
#FIIs net sell ₹5,729.60 crore while #DIIs net buy ₹7,000.68 crore in equities today (provisional) MarketTrends https://earnfree.in/latest #COMMODITY #FIIs net sell ₹5,729.60 crore while […]
INTRADAY UPDATE: BUY MCX NATURALGAS SEP 190 PE, SL TRADED AT 14.3 #commodity #StockMarket #FinancialNews #TradingGlobal https://earnfree.in INTRADAY UPDATE: BUY MCX NATURALGAS SEP 190 PE, SL TRADED AT 14.3 #commodity #StockMarket #FinancialNews #TradingGlobal https://earnfree.in
- Raj Gaurav Rai
- September 2, 2024
INTRADAY UPDATE: BUY MCX NATURALGAS SEP 190 PE, SL TRADED AT 14.3 #commodity #StockMarket #FinancialNews #TradingGlobal https://earnfree.in INTRADAY UPDATE: BUY MCX NATURALGAS SEP 190 PE, […]
ydus has received marketing approval from Mexican regulatory authority COFEPRIS for Mamitra, a Trastuzumab biosimilar. #FinancialNews #Trading  ydus has received marketing approval from Mexican regulatory authority COFEPRIS for Mamitra, a Trastuzumab biosimilar. #FinancialNews #Trading
- Raj Gaurav Rai
- August 1, 2024
ydus has received marketing approval from Mexican regulatory authority COFEPRIS for Mamitra, a Trastuzumab biosimilar. #FinancialNews #Trading  ydus has received marketing approval from Mexican regulatory […]